Eledon (ELDN): Betting on an Immunology Win That Could Reprice a Small Cap
Eledon Pharmaceuticals sits at an unusual intersection: a clinical-stage biotech with a broadly applicable immunology asset (tegoprubart) that produced encouraging Phase 2 kidney transplant data and was used in a high-profile pig-to-human transplant. With a market cap near $276M and a clean balance sheet, ELDN is a speculative long for investors wi…